BioCentury | Nov 3, 2017
Strategy

Broadening Novartis’ NET

...pipeline: prostate cancer candidate 177Lu PSMA-R2, which targets prostate-specific membrane antigen (PSMA; FOLH1; GCPII); and 68Ga-NeoBOMB1...
BioCentury | Nov 3, 2017
Company News

Novartis offers $3.9B to acquire Advanced Accelerator

...preclinical prostate cancer candidate 177Lu PSMA-R2 and its companion diagnostic, 68GA PSMA-R2; and 177Lu-NeoBOMB1 and 68Ga-NeoBOMB1...
BioCentury | Oct 30, 2017
Company News

Novartis offers $3.9B to acquire Advanced Accelerator

...prostate cancer candidate 177Lu PSMA-R2 and its companion diagnostic, 68GA PSMA-R2 ; and 177Lu-NeoBOMB1 and 68Ga-NeoBOMB1...
Items per page:
1 - 3 of 3